DE3766308D1 - Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. - Google Patents

Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Info

Publication number
DE3766308D1
DE3766308D1 DE8787305086T DE3766308T DE3766308D1 DE 3766308 D1 DE3766308 D1 DE 3766308D1 DE 8787305086 T DE8787305086 T DE 8787305086T DE 3766308 T DE3766308 T DE 3766308T DE 3766308 D1 DE3766308 D1 DE 3766308D1
Authority
DE
Germany
Prior art keywords
carbidopa
levodopa
combination
active substances
delayed delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787305086T
Other languages
German (de)
English (en)
Inventor
Robert E Dempski
Donald W Nibbelink
Edward C Scholtz
Scott A Reines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3766308(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE3766308D1 publication Critical patent/DE3766308D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE8787305086T 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. Expired - Lifetime DE3766308D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16

Publications (1)

Publication Number Publication Date
DE3766308D1 true DE3766308D1 (de) 1991-01-03

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787305086T Expired - Lifetime DE3766308D1 (de) 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Country Status (17)

Country Link
EP (1) EP0253490B1 (enExample)
JP (1) JPS6354319A (enExample)
KR (1) KR950002882B1 (enExample)
AT (1) ATE58473T1 (enExample)
AU (1) AU597670B2 (enExample)
CY (1) CY1578A (enExample)
DE (1) DE3766308D1 (enExample)
DK (1) DK170514B1 (enExample)
ES (1) ES2018548B3 (enExample)
GR (1) GR3001102T3 (enExample)
HK (1) HK56191A (enExample)
IE (1) IE60508B1 (enExample)
IL (1) IL82823A (enExample)
NZ (1) NZ220599A (enExample)
PT (1) PT85049B (enExample)
SG (1) SG52191G (enExample)
ZA (1) ZA874233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2007055329A1 (ja) 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
JP2016520540A (ja) * 2013-03-28 2016-07-14 オムニアクティブ ヘルス テクノロジーズ リミテッド 脳内におけるカロテノイドの神経保護作用
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
GB2644236A (en) 2024-09-24 2026-03-25 Novumgen Ltd Orodispersible tablet composition containing carbidopa and levodopa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
DE3271647D1 (en) * 1981-07-08 1986-07-17 Key Pharma Polymeric diffusion matrix containing propranolol
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK170514B1 (da) 1995-10-09
KR880000086A (ko) 1988-03-23
ZA874233B (en) 1987-12-14
IE871559L (en) 1987-12-16
GR3001102T3 (en) 1992-05-12
NZ220599A (en) 1990-10-26
AU597670B2 (en) 1990-06-07
IL82823A (en) 1991-03-10
JPS6354319A (ja) 1988-03-08
EP0253490B1 (en) 1990-11-22
DK302587D0 (da) 1987-06-15
KR950002882B1 (ko) 1995-03-28
IL82823A0 (en) 1987-12-20
CY1578A (en) 1991-12-20
IE60508B1 (en) 1994-07-27
HK56191A (en) 1991-07-26
DK302587A (da) 1987-12-17
ATE58473T1 (de) 1990-12-15
AU7422887A (en) 1987-12-17
EP0253490A1 (en) 1988-01-20
SG52191G (en) 1991-08-23
JPH0445B2 (enExample) 1992-01-06
ES2018548B3 (es) 1991-04-16
PT85049A (en) 1987-07-01
PT85049B (pt) 1990-03-08

Similar Documents

Publication Publication Date Title
DE3875705D1 (de) Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe.
ATE58473T1 (de) Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
EP0196769A3 (en) A novel transdermal pharmaceutical absorption dosage unit
DE3881340D1 (de) Vorrichtung zur transdermalen applikation von medikamenten.
DE3879853D1 (de) Klebstoffzusammensetzung, zusammensetzung mit kontrollierter wirkstofffreisetzung und system zur transdermalen anwendung von arzneien.
DK0388306T3 (da) Farmaceutisk præparat til behandling af smerte knyttet til herpes zoster og postherpetisk neuralgi ved topisk påføring af l
DK164482C (da) Middel i form af folier til transdermal applikation af stoffer, der er virksomme som laegemidler, samt fremgangsmaade til fremstilling heraf
PT93430A (pt) Processo para a preparacao de um sistema terapeutico transdermico para a para a aministracao de substancias activas em fases e sua utilizacao para a administracao local ou sistemica de substancias activas
FI104151B1 (fi) Laite vaikuttavan aineen luovuttamiseksi ohjatusti

Legal Events

Date Code Title Description
8364 No opposition during term of opposition